Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a relatively rare type of cancer with a poor prognosis. Despite the combination of chemotherapy and advances in targeted therapy, which have potentially improved the prognosis of patients with BTC, research on outcomes remains inadequate. The present study thus analyzed the survival trends of patients with BTC. The present study used anonymized data from a public national database and focused on 13,600 individuals diagnosed with BTC between 2015 and 2020. The overall and 1-year mortality rates were analyzed according to cancer anatomic sites, along with the impact of comorbidities, such as diabetes and hepatitis on these rates. A total of 13,600 patients were included in the analysis; 26.31% of the patients had intrahepatic BTC, 27.46% had extrahepatic BTC and 46.24% had gallbladder (GB) cancer. For all BTC types, the 1-year survival hazard ratio (HR) in 2018 was 0.992 compared with that in 2015, and 0.986 in 2019. Compared with intrahepatic BTC, the 1-year survival rate was 0.349 for GB cancer and 0.641 for extrahepatic BTC. Patients with diabetes had an HR of 1.318 compared with those without diabetes. For patients with BTC previously diagnosed with GB stones, the survival HR was 0.902, compared to those without GB stones. On the whole, the analysis of national healthcare big data indicated an improvement in the overall prognosis of patients with BTC from 2018. Moreover, these data highlight that the prognosis of patients with BTC is influenced by the anatomical location of the cancer, and that co-existing medical conditions in patients affect the survival rate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775868 | PMC |
| http://dx.doi.org/10.3892/mi.2025.214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of second-line chemotherapy regimens in advanced biliary tract cancer: a systematic review, meta-analysis, and population-based cohort study.
Int J Surg
September 2025
Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options, especially after first-line chemotherapy failure. FOLFIRINOX, though established for pancreatic cancer, has shown promise in advanced BTC, yet its role as a second-line treatment remains unclear. To address this gap, we conducted a retrospective cohort study to evaluate the efficacy and safety of FOLFIRINOX and performed a systematic review with meta-analysis to compare its outcomes with currently recommended regimens, including FOLFIRI, FOLFOX, and nal-IRI/FL.
View Article and Find Full Text PDFIs it a new era for intrahepatic cholangiocarcinoma?
Crit Rev Oncol Hematol
September 2025
Medical Oncology Unit, Department of Molecular and Clinical Sciences, AOU delle Marche, Polytechnic University of Marche, Ancona, Italy. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) is increasingly considered as a separate entity from other biliary tract cancers (BTCs), due to differences in aetiology, risk factors, pathobiology, anatomical and molecular biology characteristics. Surgery is the only curative option for the ∼ 30 % who are diagnosed with a resectable disease, while liver-directed therapies (LDTs - i.e.
View Article and Find Full Text PDFGLIM Criteria as Prognostic Factor in Patients Undergoing Adjuvant S-1 Chemotherapy for Biliary Tract Cancer.
Cancer Diagn Progn
September 2025
Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Background/aim: Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain.
View Article and Find Full Text PDFA survival prediction model for biliary tract cancer based on least absolute shrinkage and selection operator-cox regression.
Ann Med
December 2025
Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Background: Biliary tract cancer (BTC) is a digestive tract tumor with low incidence, high malignancy, and short survival times. Abnormal lipid metabolism may be related to the occurrence and development of tumors; therefore, we constructed a survival prediction model for patients with BTC using clinical data that included lipid indicators rarely considered in previous studies.
Patients And Methods: Clinical and pathological data were collected from 124 patients with BTC.
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer.
Expert Opin Biol Ther
September 2025
Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Introduction: Zanidatamab is a humanized biparatopic IgG antibody that selectively inhibits HER2 signaling pathway by targeting two distinct epitopes in the extracellular domains II and IV of HER2. Zanidatamab received accelerated approval from the United States Food and Drug Administration for the treatment of HER2-positive (immunohistochemistry [IHC] 3+) biliary tract cancer (BTC) in November 2024. Additionally, zanidatamab received approval for the treatment of HER2 IHC 3+ BTC from the European Medicines Agency in June 2025, and from National Medical Products Administration of China in May 2025.
View Article and Find Full Text PDF